Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), a precision medicine company that combines epigenetics, genetics, and artificial intelligence, is strategically positioned to address the growing global burden of cardiovascular disease. According to a recent article, the company aims to reduce the impact of heart disease by developing a platform that integrates AI with epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood sample.
The article highlights that cardiovascular disease continues to place a profound burden on individuals, economies, and healthcare systems worldwide. Cardio Diagnostics is responding to this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. The company’s offerings integrate epigenetic markers, including DNA methylation, with genetic data to generate individualized cardiovascular risk assessments. This approach aligns with the broader movement toward precision medicine, where healthcare decisions are increasingly guided by a patient’s unique molecular profile rather than generalized population-based metrics.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging its proprietary AI-driven Integrated Genetic-Epigenetic Engine, known as Core Technology, for cardiovascular disease. Its goal is to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
For more details, the full article can be accessed at https://ibn.fm/8hqFN. The latest news and updates regarding CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
